Sanofi Genzyme Breakfast Symposium – Importance of a Personalized Approach in the Risk Stratification of Patients with DTC

     

     

    Importance of a Personalized Approach in the Risk Stratification of Patients with DTC

    Date: Saturday, July 29th
    Time: 6:00 am – 7:30 am
    Location: Marina Ballroom

    Chair: Steven Sherman
    Panelists: 
    Jeremy Freeman, Leonard Wartofsky, Douglas Van Nostrand

     

    2015 ATA guidelines have recommended an individualized approach to the management of patients with differentiated thyroid cancer. This strategy will help to assess response to initial treatment as well as guide disease surveillance and therapeutic management decision-making. Clinicians must decide whether to perform lobectomy, total thyroidectomy as well as lymph node dissection when appropriate. Pathology reports are key to informing disease status as are imaging studies using neck ultrasonography and/or 131I whole body scans. Thyroglobulin and stimulated thyroglobulin testing are also effective tools which can be employed. With objective information in hand, clinicians will be able to more confidently decide which patients can now be safely monitored and which may benefit from more surgery or radioactive iodine. The degree of available information, experience level of multidisciplinary team and patient preferences play an important role in the decision to treat and follow-up of DTC.  Brief didactic presentations will illustrate the need for individualization followed by panel case discussions.

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD